Assessing the immunogenicity of three different inactivated polio vaccine schedules for use after oral polio vaccine cessation, an open label, phase IV, randomized controlled trial
| Autor: | Asma Binte Aziz, Kristin VanderEnde, M. Steven Oberste, Khalequ Zaman, Qian An, Mark A. Pallansch, Mohammed Yunus, Sara Khan, Cynthia J. Snider, Concepcion F. Estivariz, Abhijeet Anand, Stephanie D. Kovacs |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pediatrics
medicine.medical_specialty Antibodies Viral medicine.disease_cause Article law.invention Randomized controlled trial law medicine Humans Seroconversion Child Bangladesh General Veterinary General Immunology and Microbiology business.industry Immunogenicity Poliovirus Public Health Environmental and Occupational Health Antibody titer Infant social sciences Vaccination Poliovirus Vaccine Inactivated Infectious Diseases Immunization Poliovirus Vaccine Oral Inactivated Poliovirus Vaccine Molecular Medicine business Poliomyelitis |
| Zdroj: | Vaccine |
| ISSN: | 0264-410X |
| Popis: | BACKGROUND: After global oral poliovirus vaccine (OPV) cessation, the Strategic Advisory Group of Experts on Immunization (SAGE) currently recommends a two-dose schedule of inactivated poliovirus vaccine (IPV) beginning ≥14-weeks of age to achieve at least 90% immune response. We aimed to compare the immunogenicity of three different two-dose IPV schedules started before or at 14-weeks of age. METHODS: We conducted a randomized, controlled, open-label, inequality trial at two sites in Dhaka, Bangladesh. Healthy infants at 6-weeks of age were randomized into one of five arms to receive two-dose IPV schedules at different ages with and without OPV. The three IPV-only arms are presented: Arm C received IPV at 14-weeks and 9-months; Arm D received IPV at 6-weeks and 9-months; and Arm E received IPV at 6 and 14-weeks. The primary outcome was immune response defined as seroconversion from seronegative ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect